Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Dec 1;18(23):2893-904.
doi: 10.1101/gad.1256804. Epub 2004 Nov 15.

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

James Brugarolas  1 , Kui Lei, Rebecca L Hurley, Brendan D Manning, Jan H Reiling, Ernst Hafen, Lee A Witters, Leif W Ellisen, William G Kaelin Jr
Affiliations

Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex

James Brugarolas et al. Genes Dev. .

Abstract

Mammalian target of rapamycin (mTOR) is a central regulator of protein synthesis whose activity is modulated by a variety of signals. Energy depletion and hypoxia result in mTOR inhibition. While energy depletion inhibits mTOR through a process involving the activation of AMP-activated protein kinase (AMPK) by LKB1 and subsequent phosphorylation of TSC2, the mechanism of mTOR inhibition by hypoxia is not known. Here we show that mTOR inhibition by hypoxia requires the TSC1/TSC2 tumor suppressor complex and the hypoxia-inducible gene REDD1/RTP801. Disruption of the TSC1/TSC2 complex through loss of TSC1 or TSC2 blocks the effects of hypoxia on mTOR, as measured by changes in the mTOR targets S6K and 4E-BP1, and results in abnormal accumulation of Hypoxia-inducible factor (HIF). In contrast to energy depletion, mTOR inhibition by hypoxia does not require AMPK or LKB1. Down-regulation of mTOR activity by hypoxia requires de novo mRNA synthesis and correlates with increased expression of the hypoxia-inducible REDD1 gene. Disruption of REDD1 abrogates the hypoxia-induced inhibition of mTOR, and REDD1 overexpression is sufficient to down-regulate S6K phosphorylation in a TSC1/TSC2-dependent manner. Inhibition of mTOR function by hypoxia is likely to be important for tumor suppression as TSC2-deficient cells maintain abnormally high levels of cell proliferation under hypoxia.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Tsc2 regulates mTOR in response to hypoxia. (A) Western blot analysis of Tsc2+/+ and Tsc2-/- MEFs. (Hif) Hif-1α and/or Hif-2α; (S6K-P) S6K phosphorylated T389; (S6-P) S6 phosphorylated on S235/236. Left panel shows MEF in 0.05% serum or following serum addition (10% serum for 45 min) pretreated or not with rapamycin (1.5 h prior to serum addition). Right panel shows MEFs exposed to hypoxia for the indicated periods of time. (B) Western blot analysis of Tsc1+/+ and Tsc1-/- mouse 3T3 cells treated with hypoxia for the indicated periods of time. (C) Western blot analysis of input (left) and 7mGTP-bound (right) proteins from extracts of Tsc2+/+ and Tsc2-/- MEFs exposed to hypoxia for the indicated periods of time. (D,E) Western blot analysis of extracts from Tsc2+/+ and Tsc2-/- MEFs exposed to hypoxia for the indicated periods of time. In E all the cells were treated with rapamycin for 26 h prior to lysis regardless of the duration of hypoxia.
Figure 2.
Figure 2.
Tsc2 is both necessary and sufficient for the regulation of S6 phosphorylation by hypoxia. (A) Western blot analysis of Tsc2-/- MEFs retrovirally transduced with either a Tsc2 expression vector or an empty vector and treated with hypoxia for the indicated periods of time. Tsc2+/+ MEFs are included as controls. (B) Western blot analysis of HEK293 cells transfected with two different synthetic Tsc2 siRNAs (a and b) or a scrambled siRNA (Sc) and exposed to hypoxia for the indicated periods of time.
Figure 3.
Figure 3.
Tsc2 loss confers a proliferative advantage under hypoxic conditions. (A) Proliferation rates of Tsc2-/- and Tsc2+/+ MEFs under normoxic conditions. (B) Proliferation rates under hypoxic conditions of Tsc2+/+ and Tsc2-/- MEFs (treated or not with rapamycin). Error bars for A and B equal one standard deviation (n = 3). Note different Y-axis scales in A and B. (C) Western blot analysis of Tsc2+/+ and Tsc2-/- MEFs cultured in parallel under hypoxic conditions for the indicated number of days.
Figure 4.
Figure 4.
mTOR regulation by hypoxia is both AMPK and Lkb1 independent. (A) Western blot analysis of extracts of Tsc2+/+ and Tsc2-/- MEFs treated with AICAR for the indicated periods of time. (ACC-P) Acetyl-CoA carboxylase phosphorylated at S79; (AMPK-P) AMPK phosphorylated at T172. (B) Western blot analysis of Tsc2+/+ MEFs after 4 h of treatment with either hypoxia or AICAR. (C) In vitro AMPK kinase assay of the same extracts used in B immunoprecipitated in antibody excess with a polyclonal anti-AMPK (α AMPK) antibody or normal rabbit IgG (IgG). Samples were normalized for protein concentration prior to immunoprecipitation. Error bars equal one standard deviation (n = 3). Also shown are background activities of immunoprecipitates incubated in the absence of substrate (SAMS peptide). (D) Western blot analysis of Tsc2+/+ cells pretreated or not with the AMPK inhibitor compound C and exposed to either AICAR or hypoxia for the indicated periods of time. All cells treated with compound C were exposed to the drug for 9.5 h. (E,F) Western blot of Lkb1+/+ or Lkb1-/- MEFs treated with AICAR (E) or hypoxia (F) for the indicated periods of time.
Figure 5.
Figure 5.
Down-regulation of mTOR function by hypoxia requires Redd1. (A) Western blot analysis of Tsc2+/+ MEFs pretreated (30 min prior to initiation of the hypoxia time course) or not, with Actinomycin D and exposed to hypoxia for the indicated periods of time. Shown in parallel, analysis of Tsc2+/+ cells treated with Actinomycin D for the indicated periods of time. Northern blot (B) and Western blot (C) analysis of Redd1+/+ and Redd1-/- MEFs treated with hypoxia for the indicated periods of time.
Figure 6.
Figure 6.
Tsc2 but not Redd1 is required for growth factor signaling. Western blot analysis of Tsc2+/+ and Tsc2-/- MEFs (A) or Redd1+/+ and Redd1-/- MEFs (B) after serum deprivation for the indicated periods of time.
Figure 7.
Figure 7.
Down-regulation of S6K1 phosphorylation by Redd1 and Redd2. (A) Western blot analysis of anti-HA immunoprecipitates (top) or whole-cell extracts (bottom) from HEK293 cells transfected with HA-tagged expression vectors encoding Redd1 (R1), Redd1 mutant lacking central domain (R1dC), Redd2 (R2), Redd1 and Redd2 (R1 + R2), or an empty vector (pcDNA3). HA-S6K1 (S6K) was cotransfected where indicated. Rapamycin was added several hours prior to cell harvest where indicated. (B) Western blot analysis of anti-HA immunoprecipitates (bottom) or whole-cell extracts (top) from HeLa cells exponentially growing under serum-rich conditions transfected with siRNAs (Sc, scrambled; Tsc2, b and a) and expression vectors as in A. Rapamycin was added several hours prior to cell harvest where indicated. Ig(H) indicates immunoglobulin heavy chain. (C) Western blot analysis of HA-Redd1 inducible U2OS cells transfected with the indicated siRNAs and stimulated to produce Redd1 with tetracycline for the indicated periods of time.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Arsham A.M., Howell, J.J., and Simon, M.C. 2003. A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets. J. Biol. Chem. 278: 29655-29660. - PubMed
    1. Brugarolas J. and Kaelin, W.G. 2004. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 6: 7-10. - PubMed
    1. Brugarolas J., Vazquez, F., Reddy, A., Sellers, W.R., and Kaelin, W.G. 2003. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4: 147-156. - PubMed
    1. Cantley L.C. 2002. The phosphoinositide 3-kinase pathway. Science 296: 1655-1657. - PubMed
    1. Carling D. 2004. The AMP-activated protein kinase cascade—A unifying system for energy control. Trends Biochem. Sci. 29: 18-24. - PubMed

Publication types